Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms iCAMMS-IST
- 11 Dec 2013 Planned end date changed from 1 Feb 2018 to 1 Dec 2018 as reported by ClinicalTrials.gov.
- 11 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jan 2013 Planned number of patients changed from 20 to 25 as reported by ClinicalTrials.gov.